Terumo Receives FDA Go-Ahead To Start Trial As Part Of U.S./Japan Pilot
This article was originally published in PharmAsia News
Executive Summary
Japanese device maker Terumo on May 12 announced it had received conditional U.S. FDA approval to begin enrollment for a U.S. clinical trial of its Misago superficial femoral artery stent